GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Microbix Biosystems Inc (TSX:MBX) » Definitions » LT-Debt-to-Total-Asset

Microbix Biosystems (TSX:MBX) LT-Debt-to-Total-Asset : 0.17 (As of Mar. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Microbix Biosystems LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Microbix Biosystems's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.17.

Microbix Biosystems's long-term debt to total assets ratio declined from Mar. 2023 (0.19) to Mar. 2024 (0.17). It may suggest that Microbix Biosystems is progressively becoming less dependent on debt to grow their business.


Microbix Biosystems LT-Debt-to-Total-Asset Historical Data

The historical data trend for Microbix Biosystems's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbix Biosystems LT-Debt-to-Total-Asset Chart

Microbix Biosystems Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.31 0.18 0.17 0.18

Microbix Biosystems Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.18 0.18 0.18 0.17

Microbix Biosystems LT-Debt-to-Total-Asset Calculation

Microbix Biosystems's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (A: Sep. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Sep. 2023 )/Total Assets (A: Sep. 2023 )
=6.38/35.653
=0.18

Microbix Biosystems's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )/Total Assets (Q: Mar. 2024 )
=6.447/37.922
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Microbix Biosystems  (TSX:MBX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Microbix Biosystems LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Microbix Biosystems's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Microbix Biosystems (TSX:MBX) Business Description

Traded in Other Exchanges
Address
265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3
Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company's operating segment includes Antigen, QAPs DxTM and Other Includes Kinlytic. It generates maximum revenue from the Antigen QAPs segment. Geographically, it derives a majority of revenue from North America.
Executives
James Stuart Currie Senior Officer

Microbix Biosystems (TSX:MBX) Headlines

No Headlines